Characterizations of Cancer Gene Mutations in Chinese Metastatic Breast Cancer Patients

Zhonghua Tao, Ting Li, Zhe Feng, Chang Liu, Yilin Shao, Mingyu Zhu, Chengcheng Gong, Biyun Wang, Jun Cao, Leipin Wang, Yiqun Du, Analyn Lizaso, Bing Li, Jian Zhang, Xichun HuFrontiers in Oncology 2020 · DOI

TL;DR

This study characterizes the genomic mutation landscape of metastatic breast cancer (mBC) in Chinese women using liquid biopsies. They found distinct mutation profiles compared to Caucasian populations and early-stage breast cancer, highlighting the importance of ethnicity and disease stage in understanding mBC. This research underscores the utility of ctDNA for real-time monitoring and personalized treatment strategies.

What Problem Does This Paper Address?

Breast cancer is a highly heterogeneous disease, and understanding its molecular subtypes is crucial for effective treatment. While molecular profiling has advanced mBC management, the specific genomic mutation landscape of Chinese women with metastatic breast cancer remained largely unexplored. Previous studies primarily focused on Caucasian populations, leaving a knowledge gap regarding potential ethnic-specific differences in mBC genetics. This study aims to fill that gap by providing a comprehensive analysis of mutations in Chinese mBC patients, comparing it with existing datasets to identify unique characteristics and potential implications for treatment.

Methods

The researchers employed Next-Generation Sequencing (NGS) on circulating tumor DNA (ctDNA) extracted from plasma samples of 290 Chinese women with metastatic breast cancer. They utilized commercially available gene panels, one focusing on 108 breast cancer-related genes and another on 520 cancer-related genes, with 91 genes overlapping between the two. This allowed for the detection of single nucleotide variations (SNVs), insertion-deletion variants (Indels), copy number amplifications (CNAs), and other alterations. The ctDNA mutation profiles were then compared with publicly available datasets from the Memorial Sloan Kettering Cancer Center (MSKCC) and the Pan-cancer Analysis of Whole Genomes (PCAWG) to identify differences between Chinese and Caucasian mBC patients.

Datasets

  • Primary Dataset: ctDNA samples from 290 Chinese women with metastatic breast cancer, collected between January 2017 and April 2019.
  • Publicly Available Datasets for Comparison:
    • Memorial Sloan Kettering Cancer Center (MSKCC) dataset (1,855 Caucasian patients).
  • Pan-cancer Analysis of Whole Genomes (PCAWG) dataset (447 Caucasian patients).

Key Insights and Ideas

  • Ethnic-Specific Mutation Profiles: The study revealed significant differences in mutation rates between Chinese and Caucasian metastatic breast cancer patients, particularly in genes like TP53 and PIK3CA, suggesting that ethnicity plays a role in the genomic landscape of mBC.
  • Liquid Biopsy's Power: The high mutation detection rate (80.7%) using ctDNA from plasma highlights the effectiveness of liquid biopsies for capturing tumor heterogeneity and providing real-time insights into metastatic disease, even with limited tumor tissue.
  • Metastasis Association: Specific mutations, such as those in PIK3CA, PTEN, and RB1, were found to be associated with a higher likelihood of liver metastasis, and maximum allelic fraction (maxAF) of TP53, RB1, and PIK3CA mutations correlated with multiple organ metastasis. This suggests potential predictive value for metastasis development.
  • Subtype-Specific Differences: The study identified distinct mutation patterns across different molecular subtypes of breast cancer, with TP53 mutations being more frequent in triple-negative breast cancer (TNBC) and HR-/HER2+ subtypes, while PIK3CA mutations were more prevalent in HR-positive subtypes.
  • Early vs. Metastatic Distinction: The findings suggest that metastatic breast tumors have a different molecular profile compared to early-stage tumors, emphasizing the need for distinct analytical approaches for each stage.

Key Results

  • A total of 1,201 mutations across 91 genes were detected in 234 out of 290 patients, yielding a mutation detection rate of 80.7%.
  • The most frequently mutated gene was TP53 (64.1%), followed by PIK3CA (31%), PTEN (11%), and RB1 (10%).
  • Copy number amplifications (CNAs) were observed in genes like MYC (14.1%), FGFR1 (13.3%), and CCND1 (6.6%).
  • TP53 mutations were significantly more frequent in TNBC, HR-/HER2+, and HR+/HER2+ subtypes compared to HR+/HER2- subtypes (P < 0.01).
  • PIK3CA mutations were more frequent in HR+/HER2+, HR+/HER2-, and HR-/HER2+ subtypes, and less common in TNBC (P < 0.01).
  • Pathogenic BRCA1/2 germline mutations were found in 5.9% of the cohort (4.4% in TNBC).
  • Compared to Caucasian datasets (MSKCC and PCAWG), Chinese TNBC patients showed significantly lower TP53 mutation rates (73.0% vs. 91.5%, P < 0.001).
  • Chinese HR+/HER2- patients had significantly higher rates of FGFR1 (3.3% vs. 0.7%, P = 0.035) and TP53 (46.2% vs. 27.7%, P < 0.001) mutations.

Limitations and Future Work

The authors acknowledge several limitations:

  • Lack of Tissue Samples: The study relied solely on plasma ctDNA, and the absence of matched tissue samples limits direct comparison of molecular profiles.
  • ctDNA Limitations for CNVs: The fragment size of ctDNA makes detecting copy number variations (CNVs) technically challenging, potentially impacting the accuracy of CNA analysis.
  • Baseline Sample Collection: Blood samples were not collected at a uniform time point for all patients, and most had undergone multiple treatment lines, which could theoretically influence results (though the study found no significant impact on allelic fraction or mutation profiles).
  • Single-Center Study: The study was conducted at a single center with a limited number of patients, necessitating further validation in larger, multi-center prospective studies.
  • Prognostic Value: The overall survival data for the cohort was not yet mature, preventing a definitive assessment of the prognostic value of frequently altered genes.

Future work should focus on validating these findings in larger cohorts, exploring the therapeutic implications of these distinct mutation profiles, and further investigating the role of ctDNA in guiding treatment decisions for Chinese metastatic breast cancer patients.

Summary updated

Abstract

<b>Background:</b> Breast cancer (BC) is a type of disease with high heterogeneity. Molecular profiling, by revealing the intrinsic nature of its various subtypes, has extensively improved the therapeutic management of BC patients. However, the genomic mutation landscape of Chinese metastatic BC has not been fully explored. <b>Methods:</b> Matched plasma and mononuclear cells from 290 Chinese women with metastatic BC were sequenced using either of the two commercially-available panels consisting of 520 cancer-related and 108 BC-related genes. Both panels cover the same critical regions of 91 genes. The circulating tumor DNA mutation profile from our cohort was then compared with publicly-available metastatic BC datasets from Memorial Sloan Kettering Cancer Center (MSKCC) and Pan-cancer analysis of whole genomes (PCAWG). <b>Results:</b> A total of 1,201 mutations spanning 91 genes were detected from 234 patients, resulting in a mutation detection rate of 80.7%. TP53 (64.1%) was the gene with highest mutation frequency, followed by PIK3CA (31%), PTEN (11%), and RB1 (10%). Copy number amplifications (CNAs) in MYC (14.1%), FGFR1 (13.3%), CCND1 (6.6%), FGF3 (6.6%), FGF4 (6.2%) and FGF19 (6.2%) were also detected from our cohort. TP53 mutations were significantly more frequent among triple negative BC (TNBC), HR-/HER2+, and HR+/HER2+ BC, while less common in HR+/HER2- (<i>P</i> < 0.01). Meanwhile, PIK3CA mutations were significantly more frequent among HR+/HER2+, HR+/HER2-, and HR-/HER2+ BC, while less common in TNBC (<i>P</i> < 0.01). Pathogenic or likely pathogenic BRCA1/2 germline mutations were detected in 5.9% of the cohort and 4.4% in TNBC subgroup. Maximum allelic fraction (maxAF) of TP53, RB1, and PIK3CA mutations were associated with multiple organ metastasis. Patients with PIK3CA, PTEN, and RB1 mutation were more likely to have liver metastasis (<i>P</i> < 0.02). Compared with MSKCC and PCAWG dataset, Chinese patients had observably difference in genetic variation rates in different molecular subtypes (TNBC: TP53 73.0 vs. 91.5%, <i>P</i> < 0.001; PIK3CA 21.2 vs. 13.2%, <i>P</i> = 0.061; HR+/HER2-: FGFR1 3.3 vs. 0.7%, <i>P</i> = 0.035; TP 53 46.2 vs. 27.7%, <i>P</i> < 0.001; RB1 6.6 vs. 2.7%, <i>P</i> = 0.046; CDKN2A 7.7 vs. 1.0%, <i>P</i> < 0.001; PIK3CA 30.8 vs. 44.2%, <i>P</i> = 0.012; CDH1 1.1 vs. 18.2%, <i>P</i> < 0.001; GATA3 7.7 vs. 17.2%, <i>P</i> = 0.02). <b>Conclusions:</b> A distinct gene mutation profile was elucidated in Chinese women with metastatic BC, justifying further research. Liquid biopsy provides a quick, real-time, and minimally invasive tool for future clinical trial and routine practice.
BibTeX
@inproceedings{tao2020characterizations,
  author = {Zhonghua Tao and Ting Li and Zhe Feng and Chang Liu and Yilin Shao and Mingyu Zhu and Chengcheng Gong and Biyun Wang and Jun Cao and Leipin Wang and Yiqun Du and Analyn Lizaso and Bing Li and Jian Zhang and Xichun Hu},
  title = {{Characterizations of Cancer Gene Mutations in Chinese Metastatic Breast Cancer Patients}},
  booktitle = {Frontiers in Oncology},
  year = {2020},
  doi = {10.3389/fonc.2020.01023},
}
Figure